InterAx wins new partner from one of Germany's oldest universities

InterAx Biotech AG and Peter Kolb a professor at the Philipps-University Marburg have entered a collaboration to fuse the unique biosensor and systems biology platform with the expertise on virtual screening for the development of lead compounds with highly tailored pharmacological properties for an undisclosed target.

InterAx is a spinoff from the ETH Zurich and the Paul Scherrer Institute (PSI). The startup is building a unique drug discovery platform for identification of functionally selective G protein-coupled receptor (GPCR) drug candidates. The InterAx core technology resides in engineering protein-based biosensors specifically sensing a particularly active state of a GPCR and in using computer algorithms to predict downstream cell signaling effects. This unique combination allows for better predictions of drug candidates properties for the desired GPCR target.

InterAx has now joined forces with Peter Kolb, a professor and group leader of the Department of Pharmaceutical Chemistry at Philipps-University Marburg. The two will work together to make new discoveries of lead compounds using highly tailored pharmacological properties.

“By combining the UMR unique expertise in virtual screening and the InterAx biosensor and systems biology platform, we will establish an iterative design and testing cycle that helps us guide the optimization of initial hits towards potent and efficacious lead matter. At the same time, we will elucidate potentially paradigm-changing principles that will aid us in future endeavours”.

About Peter Kolb
Peter Kolb is a Heisenberg Professor of Computer-Aided Drug Discovery. His research team works on the prediction and rational design of ligands with custom-tailored properties for a range of targets, predominantly from the GPCR family of membrane proteins. A key focus of this work is the synthetic accessibility of molecules, while at the same time focusing on novel, unprecedented scaffolds for the investigated receptors.

(Press release/ran)